3-Methyladenine (3-MA)

Catalog No.S2767 Synonyms: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • MDC-labeled vacuoles were induced by AZD2014 and inhibited by autophagy inhibitor (3-MA). SMMC-7721 cells were treated with AZD2014 or rapamycin at concentrations of 100 and 600 nM, respectively, for 48 hours in the presence or absence of 3-MA, and then stained with MDC. Cells were immediately observed under a confocal microscope. Cells in the control group were treated with DMSO. bars, 20 μm.

    Am J Cancer Res, 2015, 5(1): 125-139. 3-Methyladenine (3-MA) purchased from Selleck.

    PC-9/ER cells were treated with CX-4945 (5 mM) for 48 h in the presence or absence of 3-MA (2 mM) and Atg7 siRNA (100 nM). Cleavage of PARP-1 and caspase-3 was shown by Western blot analysis. CT: without CX-4945; CX: CX-4945; CX+G: CX-4945 + gefitinib; CX+E: CX-4945 + erlotinib.

    PLoS One, 2014, 9(12): e114000 . 3-Methyladenine (3-MA) purchased from Selleck.

  • A: The survival ratio of AML12 cells was measured after treatment with rapamycin or 3-MA; B: Western blot was used to detect the expression of LC3 and P62 in AML12 cells treated with Rapamycin or 3-MA.

    World J Gastroenterol, 2016, 22(18): 4501-4514.. 3-Methyladenine (3-MA) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfOPGk{dU1? NFK2SVEzcA>? MYfEUXNQ NHnLZ4tz\WS3Y3XzJIdzd3e2aDDpcohq[mm2b4L5JIVn\mWldDDv[kBDTE2F NYDkOW0zOjV5MU[1OlE>
A549  M37Tcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDYN41O MWSybC=> M3H5[mROW09? MVTy[YR2[2W|IHfyc5d1cCCrbnjpZol1d3K7IHXm[oVkfCCxZjDCSG1E M{XMXlI2PzF4NU[x
95D M3u4[mFxd3C2b4Ppd{BCe3OjeR?= NXrkNlhPPW2P M1KwSlJp MYrEUXNQ Mo\jbY5pcWKrdIOgRmROSy2rbnT1Z4VlKGGyb4D0c5Rq[yClZXzsJIRm[XSq NHz1SG0zPTdzNkW2NS=>
A549  M1\NXmFxd3C2b4Ppd{BCe3OjeR?= M1u2UFVuVQ>? MnPCNog> M1XkTmROW09? MXrpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? MnHYNlU4OTZ3NkG=
NBL-W-S  NUTQfY1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\BT|FuVQ>? NIDrNoQ3cA>? NIfHb3JmdmijbnPld{BISU6WLU[xJJRwgGmlaYT5 M1nlXlI2OzJ|MkKy
NBL-W-S  NUjKZ3pnSXCxcITvd4l{KEG|c3H5 NXq2dZllOW2P NHz0U|A3cA>? Ml;ubY5kemWjc3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgS2FPXC14MR?= M4nCOlI2OzJ|MkKy
A2780cp  MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHzVop6OW2P MUOxbC=> MYHpcoNz\WG|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M1S5cFI2OzJ{Nkm0
A549  NWfJeJZkTnWwY4Tpc44hSXO|YYm= MkOzOY1O MXWybC=> NWnPfpNOe3WycILld5NmeyCVUFOgbY5lfWOnZDDhZ4N2dXWuYYTpc44hd2ZiTFOzMWlK MXSyOVI5PTZ{OB?=
H157 MmjKSpVv[3Srb36gRZN{[Xl? MXO1cW0> NF3tRWczcA>? M3fEOJN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=> M1;CTFI2Ojh3NkK4
MDR NWfGXGVPSXCxcITvd4l{KEG|c3H5 NH3tOFIyOG2P MmTvOog> NUXP[WNre3S{ZX7neIhmdnNidHjlJJBwf2W{IH;mJIFvfGmlYX7j[ZIh\HK3Z4O= NVTte5dMOjVyMUm3NFE>
HT-29  MVfBdI9xfG:|aYOgRZN{[Xl? NFjXOFEydU1? M3PQR|Q5cA>? MUDEUXNQ NEnSco1mdmijbnPld{Bjd3K2ZYrvcYljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? NXXpbo5OOjR6NEKxOVg>
Microglia  MoPlRZBweHSxc3nzJGF{e2G7 MoOzOY1O MlPzNlRp MV;k[YNz\WG|ZYOgbJlxd3irYT3pcoR2[2WmIHPlcIwh\GWjdHi= NHPFemMzPDhzOE[wNS=>
A2780cp NV;1WnpCSXCxcITvd4l{KEG|c3H5 NFHlVlMzNjWvTR?= M{XxelFp MmX5[IRJOk9? NYnTNZcz\W6qYX7j[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? M2jL[|I1QDF5OUS2
HepG2 MoX1SpVv[3Srb36gRZN{[Xl? NYjJOXNQPW2P MUi0bC=> M4HpRolv[3KnYYPld{BJVCC{ZXzlZZNm NY\iRllGOjR5MUO1PFc>
A549 M3OxTmFxd3C2b4Ppd{BCe3OjeR?= NFnQenI2dU1? NEO3PXc1QGh? M{LZeoRm[3KnYYPld{B1cGVicHXyZ4VvfGGpZTDv[kBk\WyuIHTlZZRpKGGwZDDlfJBz\XO|aX;uJIxmfmWuczDv[kBk[XOyYYPlMVMtKEKnY3zpck0yKGGwZDDMR|MuUUl? MU[yOFcxPjNyMx?=
U2OS MVzBdI9xfG:|aYOgRZN{[Xl? MXexNI1O MnXKNlRp MkHlbY51\W6|aX\p[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJJRp\SCXMl;TJINmdGy|IHnu[JVk\WRiYomgSI95 MnzMNlQ3OzlyMUO=
Saos-2 NYHsd3VzSXCxcITvd4l{KEG|c3H5 NXX1[oNEOTCvTR?= MUKyOIg> NInFRVNqdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhfGinIGWyU3Mh[2WubIOgbY5lfWOnZDDifUBFd3h? M1HiTVI1PjN7MEGz
A549 MXTBdI9xfG:|aYOgRZN{[Xl? MXOxNI1O NFfxeo41QGh? M{HNToFk[2WuZYLheIV{KHSqZTDy[YR2[3Srb36gc4Yh[2WubDD2bYFjcWyrdImgbY5lfWOnZDDifUBRXFh? M1vxOFI1PjJ4N{Ky
HCT116  M2jZTmFxd3C2b4Ppd{BCe3OjeR?= MV:1cW0> NFLpbFAzPGh? MnPr[Y5p[W6lZYOgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IHHwbYdmdmmw NI\rc3QzPDZ{NkWyNi=>
HGC-27 MXvGeY5kfGmxbjDBd5NigQ>? NVjmV4JHOTCvTR?= NI\SfXkycA>? MlXqbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIxwe3NiYomgVmFFODBzIH;yJG1MNTJ{ME[= NVXDcIVNOjR2MU[zOFk>
U2OS  NGnrVXlHfW6ldHnvckBCe3OjeR?= MX:wMlUwOW2P NVrqXndmPDiq MXfpcoR2[2W|IIPhcIlvd227Y3nuMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> MVmyOFM2QDN2Mh?=
MG-63 M1S5bWZ2dmO2aX;uJGF{e2G7 NWDjS3VoOC53L{HtUS=> MYm0PIg> NUf2[|d2cW6mdXPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? NXzRSJNROjR|NUizOFI>
MG-63 M{jLTmFxd3C2b4Ppd{BCe3OjeR?= NGnVfVIxNjVxMX3N Ml;PN|Jp MUHlcohidmOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxiYYDvdJRwe2m| MmqxNlQ{PTh|NEK=
MG-63 M2\hSGFxd3C2b4Ppd{BCe3OjeR?= MYCxNI1O Mn7XNVJp NWDKUWlQ\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? MYiyOFM2QDNyMR?=
NTUB1 M4LSe2Fxd3C2b4Ppd{BCe3OjeR?= MXW1cW0> M13ReFEvPWh? M3e4WJBwfGWwdHnheIV{KGOnbHXjc5hq[i2rbnT1Z4VlKGGyb4D0c5Nqew>? Ml7YNlQ{PDlzN{[=
T24 NIrYe5pCeG:ydH;zbZMhSXO|YYm= NUHLVVBnPW2P MXOxMlVp MnvmdI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ MkHINlQ{PDlzN{[=
SGC-7901  NUXSU|RrSXCxcITvd4l{KEG|c3H5 NVzGT3p4Om2P M3XPcFFp M1vRcolv[3KnYYPld{BESS12IHnu[JVk\WRiYYDvdJRwe2m| M1S5TFI1OzJzM{Sw
SMMC-7721 NYDDcGk1SXCxcITvd4l{KEG|c3H5 NE\wTJozdU1? NVLOXpp1OWh? NYLPXXBvcW6lcnXhd4V{KEODLUSgbY5lfWOnZDDhdI9xfG:|aYO= NYXtUnZMOjR|MkGzOFA>
ECSCs  MkixRZBweHSxc3nzJGF{e2G7 MonHNVBuVQ>? NYDvXmY1PGh? NX;sdmJM\GWlcnXhd4V{KHKjcHHtfYNqdi22cnXheIVlKGGyb4D0c5Nqew>? NWTTVVhwOjR|MUmxNFk>
MCF-7  M1O1OWZ2dmO2aX;uJGF{e2G7 NW\R[GJqOTCvTR?= NFOzUVYzPGh? NYrYZpNKcW6qaXLpeJMhfGinIHH1eI9xcGGpeTDpcoR2[2WmIHL5JINp\W2xdHjldoFxgSCmcoXndy=> M4S2RlI1OzF3NUe4
UOK257 NH3ZN5hCeG:ydH;zbZMhSXO|YYm= MX21cW0> Mn;rN4g> NV3xNJFJ\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?= MXqyOFMxPTZyNB?=
ACHN-5968 M2Pic2Fxd3C2b4Ppd{BCe3OjeR?= MnfHOY1O NInocZU{cA>? MXnlcohidmOnczDwZYNtcXSjeHXsMY1m\GmjdHXkJIFxd3C2b4Ppd:Kh MUiyOFMxPTZyNB?=
Huh7 MlvoRZBweHSxc3nzJGF{e2G7 NHHJVlEzdU1? M2Dp[lEzcA>? NYiz[IpETE2VTx?= NH3XXVdqdmirYnn0d{BCYkR6MEW1MYlv\HWlZXSgZ4VtdCCmZXH0bC=> NVfUfoZiOjR{OUezNFA>
Hep3B M4XXcWFxd3C2b4Ppd{BCe3OjeR?= MXmycW0> M{PRTVEzcA>? NEXiVGZFVVOR Ml3GbY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= NV;6fFJZOjR{OUezNFA>
RKO M3;EfmZ2dmO2aX;uJGF{e2G7 M3uxbFJuVQ>? MlLWNYg> M{\VUmROW09? NEjEe|JmdmijbnPld{Bk\WyuIHTlZZRpKGK7IHflcIRidmGveXPpci=> MljsNlQzQTF5N{e=
HepG2 E47 MkjkSpVv[3Srb36gRZN{[Xl? NIX0[|gzNjWvTR?= MnTOOFhp NYLieXMxcW6lcnXhd4V{KHSqZTD0c5hq[2m2eTDv[kBCSSxiQmPPMEBidmRiQ1PsOC=> MmW4NlQzPzN5M{i=
LoVo  MkXTRZBweHSxc3nzJGF{e2G7 NWjCOFJQPW2P NXT1[IV2PDiq M4DHeoVvcGGwY3XzJGRESS2rbnT1Z4VlKGGyb4D0c5Nqey5? MUCyOFIxOThzMh?=
WiDr NEHaZ|BHfW6ldHnvckBCe3OjeR?= M4HiNFExdU1? M33YSlFp NVnQb3hMcW6qaXLpeJMhWEOETD3pcoR2[2WmIFzDN{BKUSCneIDy[ZN{cW:w NWPSWm9qOjRzOUC0PFk>
H1299  NYPmOmdGTnWwY4Tpc44hSXO|YYm= MYSxNI1O M3H1WFRp NX3YenFGcW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? MlHkNlQyPzN{MEi=
H460 M4TuRmZ2dmO2aX;uJGF{e2G7 NUXhSXIyOTCvTR?= NIS4O5o1cA>? MYDpcoNz\WG|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MVWyOFE4OzJyOB?=
A549 NHTIPG1HfW6ldHnvckBCe3OjeR?= M2DWeFExdU1? NV;6NJRDPGh? M{Tk[4lvcGmkaYTzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KGm{cnHkbYF1cW:w M3jRNFI1OTR{N{O1
Hep3B NEXlfHRCeG:ydH;zbZMhSXO|YYm= MojaOY1O MWeyOIg> NHnjU5BifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM> MXiyOFA3PjZ7Mx?=
SMMC-7721 NILU[|ZCeG:ydH;zbZMhSXO|YYm= Mmi2OY1O M4PETVI1cA>? NFzyWVBifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM> MV:yOFA3PjZ7Mx?=
HO8910 MmHNRZBweHSxc3nzJGF{e2G7 NFLsRYMyOG2P NXniXFhnOTKq NHz2XmpmdmijbnPld{BDOTlvaX7keYNm\CCjcH;weI9{cQ>? MmS0NlM6QDN4MUC=
MCF7 MXnGeY5kfGmxbjDBd5NigQ>? NGi3N2o2dU1? MUWyOIg> M{jNbolv[3KnYYPld{BEfU9iaX7keYNm\CClZXzsJIRm[XSq M3v1cFI{QTZ{NkK5
HONE-1  MVPGeY5kfGmxbjDBd5NigQ>? NF3Hb3Q2dU1? NXfGSmQ6OWh? MUPy[ZBz\XO|ZYOgOpIudWWmaXH0[YQhWk:VIIDyc4R2[3Srb36= M{[3V|I{QDl{M{W4
HeLa MVTGeY5kfGmxbjDBd5NigQ>? Mmj2NVBuVQ>? NIDpeFMzcA>? Mlzvd5VxeHKnc4Pld{BNSzNiSVmg[ZhxemW|c3nzc44> M13UbFI{QDZ2N{O4
HepG2 NX[5c3RqTnWwY4Tpc44hSXO|YYm= MYKxNI1O NWnnZnR4OjSq NGLzWVBqdmirYnn0d{B{cVSLR1HSMUBidmRiSFLTV{1qdmS3Y3XkJIF2fG:yaHHnfS=> MUSyN|gyPzB2MB?=
SH-SY5Y M1:0UmZ2dmO2aX;uJGF{e2G7 NHjET3YydU1? NFy2b2kzPGh? NHnMUpdqdmirYnn0d{B1cGViYYX0c5Bp[We7IHnu[JVk\WRiYomgWG9EWA>? MVOyN|c1OzF2OB?=
SH-SY5Y MmPJRZBweHSxc3nzJGF{e2G7 Mm\xOY1O NXnXSXJJOWh? M3;TNoFjd2yrc3jld{Bk\Wyjc4Tyc4whdmW3cn;wdo91\WO2aY\lJIVn\mWldB?= NV7xcZoxOjN4MUmzPVU>
PC12  M1j0fGZ2dmO2aX;uJGF{e2G7 NFzFcngyOG2P MU[yOIg> M1\SW5difGW{ NF\CSJnDqGmwaHnibZR{KGOqeX3veJJ6eHOrbj3sbYtmKHC{b4TlZZNwdWGuIHHjeIl3cXS7Lh?= NGrRSZQzOzZyM{m3PS=>
OV2008 NUDI[VZ2SXCxcITvd4l{KEG|c3H5 M3nlcVVuVQ>? NU\yUmtMOjSq NUTZVHU5[2:wdnXyeJMhTlS\N{KwJJdqfGhiQ1TEVEBqdnSxIHHuJIFl\Gm2aY\lJIVn\mWldDD0c5diemS|IHvpcIxqdmdib4\hdolidiClYX7j[ZIh[2WubIO= NUjiOFZtOjN3OUKyPFE>
A2780 M3\VN2Fxd3C2b4Ppd{BCe3OjeR?= M3PRdFVuVQ>? MVyyOIg> M1vKNoNwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy| MUCyN|U6OjJ6MR?=
Saos-2  NYPrTFY3SXCxcITvd4l{KEG|c3H5 MlnFNY1O NEHWUnQ6Pmh? MVnpcoNz\WG|ZYOgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KFCFWB?= MUWyN|U3OzF5MR?=
1321N1 NVXocIR5S3m2b4TvfIlkcXS7IFHzd4F6 M{LrcFVuVQ>? Mlr0NlRp M3[wepBzd3SnY4TzJINmdGxiYXfhbY5{fCCSQ16tbY5lfWOnZDD0c5hq[2m2eR?= NGf6S|YzOzV{NUK2OS=>
SH-SY5Y NXzFV3hvS3m2b4TvfIlkcXS7IFHzd4F6 M1z2OVVuVQ>? MUWyOIg> M1;Ofolv[3KnYYPld{BRS05idH;4bYNqfHl? M{TYO|I{PTJ3Mk[1
HT-29  Mn24SpVv[3Srb36gRZN{[Xl? NFjvdFIydU1? M{LoXlQ5Nzl4aB?= NIqyc4ZqdmirYnn0d{BCVVCNIHnu[JVk\XNiYYX0c5Bp[WerYzDj[YxtKGSnYYTo NFzzXFIzOzVyOEK3Ni=>
OR6 NWL6RW9mTnWwY4Tpc44hSXO|YYm= MonsNVBuVQ>? MUS3Nog> M3f2fpN2eHC{ZYPz[ZMhUEOYIILldIxq[2G2aX;uJIFv\CCob4LtZZRqd25ib3[gZZV1d3CqYXfvd49u\XN? M2jhcFI{Ozl3OEe1
Hela  NXWydlNOTnWwY4Tpc44hSXO|YYm= Mni3OY1O NF7JNGczPGh? MnHObY5pcWKrdIOgd5Rien[jdHnvck1qdmS3Y3XkJIF2fG:yaHHnfS=> M{P5dFI{Ozl3Nke5
MCF-7  NF3GXoZHfW6ldHnvckBCe3OjeR?= MUe1cW0> NEKxZnQzPGh? M4XSNIlvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> M4DCTlI{Ozl3Nke5
HUVECs MWnGeY5kfGmxbjDBd5NigQ>? NEXMS2o{dU1? MViyOIg> NEjsVIhjdG:la4OgeIhmKHC{b4TlZ5RqfmViZX\m[YN1KG:oIILld5ZmemG2cn;sJIJ6KGmwaHnibZRqdmdiYYX0c5Bp[We7 M2rybVI{OzV6OUK4
T24 NWDBNFdbTnWwY4Tpc44hSXO|YYm= MofwNVBuVQ>? MUexbC=> NWL2b5NiemWmdXPld{B1cGViY3zlZZZi\2Vib3[gUGM{KGGodHXyJIJicWOjbHnuJJRz\WG2bXXueC=> NEHMdmMzOzN3NEC4NC=>
U251MG  MojQSpVv[3Srb36gRZN{[Xl? MojrN41O M3HzRVFp M4S5UpN2eHC{ZYPz[ZMhVEN|LVnJJJBzd3SnaX6g[ZhxemW|c3nvci=> MXmyN|M{QDZzOB?=
GTL-16  NHW3T|NCeG:ydH;zbZMhSXO|YYm= M3nIdlVuVQ>? NIS2UJkzPGh? NWTicJpLemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhd{Bkd22yYYLl[EB1dyClZXzsd{B1emWjdHXkJJdqfGhiTVXUJIlvcGmkaYTvdpM> MofXNlM{OTN2OUC=
T-47D NWry[Y43TnWwY4Tpc44hSXO|YYm= NFjtT4MyOG2P NXnLWVFCOmh? MnPmbY5pcWKrdIOgZZV1d3CqYXf5JJBzd2Onc4OgZY5lKGmwY4LlZZNmeyC{YYDhcZlkcW5iaX7keYNm\CCjcH;weI9{cXN? NGW2cWYzOzNyMECyOi=>
PaCa44 M3;2NGFxd3C2b4Ppd{BCe3OjeR?= NXnkOGx7Oi53bV2= NFLqeYUycA>? NWLxXHhzemWmdXPld:Kh\2WwaYDpck1u\WSrYYTl[EBieG:ydH;zbZM> NETKb2czOzF{NEGxNi=>
MDA-MB231 MVjGeY5kfGmxbjDBd5NigQ>? MXW1cW0> NHz5dZgycA>? NXrzXJVJcW6lcnXhd4V{KHKnc4\ldoF1em:uLX3l[IlifGWmIHPhd5Bie2ViYXP0bZZifGmxbjDhcoQh[2WubDDk[YF1cA>? MXyyN|A5QDh3MB?=
HeLa MVTBdI9xfG:|aYOgRZN{[Xl? NHvPPJgyOG2P NI[xcVMzcA>? M4DYRYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDjc{11emWjdH3lcpQhf2m2aDDQSWk> NWXjS|ZTOjNyMECxN|U>
SK-HEP-1 NFLmdpJCeG:ydH;zbZMhSXO|YYm= M{fDUlExdU1? MWqxbC=> NEXSXVlxem:2ZXP0d{Bi\2GrboP0JIF2fG:yaHHnfUBidmRiaX7keYNmeyCjcH;weI9{cXNiaX6gZpVn[Wyrbj30doVifGWmIHPlcIx{ M1LWRVIzQDV6NkS5
HepG2 MXrBdI9xfG:|aYOgRZN{[Xl? NVq3[FJ2O22P MnHLOYg> MlTRdoVlfWOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGHEdy=> MXqyNlg{PjV7NR?=
MCF-7  MliySpVv[3Srb36gRZN{[Xl? M3W3WFJuVQ>? MYOyOIg> NGW4SGRqdmirYnn0d{BifXSxcHjh[5khcW6mdXPl[EBjgSCWTdMg NUfoOlhZOjR7N{C2O|Y>
MDA-MB-231 M3vlXGZ2dmO2aX;uJGF{e2G7 MnWxNo1O MlXlNlRp Mnr1bY5pcWKrdIOgZZV1d3CqYXf5JIlv\HWlZXSgZpkhXE4EoB?= MoDnNlQ6PzB4N{[=
MCF-7  MkH3SpVv[3Srb36gRZN{[Xl? M3;vdlJuVQ>? NGXFUHQ1QGh? NILnNWFxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? MUKyOFk4ODZ5Nh?=
MDA-MB-231 Mo\jSpVv[3Srb36gRZN{[Xl? M3;EZlJuVQ>? M17CWlQ5cA>? NUC2bZhoeHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq MYiyOFk4ODZ5Nh?=
PANC-1  M3u2dWFxd3C2b4Ppd{BCe3OjeR?= MkjBNY1O NUT0SolkPDiq MXrEUXNQ MnrK[Y5p[W6lZYOgZo9zfGW8b33pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> MYCyOFg1OjF3OB?=
MDA-MB 231 MYfBdI9xfG:|aYOgRZN{[Xl? MonyOY1O NFjtVGgxNjWq M1yzPY1w\HWuYYTld{BVd2OxbXnuxs7DqGmwZIXj[YQh[XCxcITvd4l{ MXGyOFg{ODd6MR?=
Microglia  MkfvRZBweHSxc3nzJGF{e2G7 M3HGTFVuVQ>? NYLoRZBoOjSq NFHpfXpl\WO{ZXHz[ZMhcHmyb4jpZU1qdmS3Y3XkJINmdGxiZHXheIg> MUCyOFgyQDZyMR?=
A2780cp M3WwO2Fxd3C2b4Ppd{BCe3OjeR?= MnPrNk42dU1? MVexbC=> MVvk[GgzVw>? NV;CdXBU\W6qYX7j[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? M1jVSFI1QDF5OUS2
HepG2 M2HBdGZ2dmO2aX;uJGF{e2G7 NVfKdolrPW2P NYPZeIYyPGh? M3W2d4lv[3KnYYPld{Bk\WyudXzhdkBt\X[nbIOgc4YhUE{EoB?= M{Wz[FI1PzF|NUi3
U2OS MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPrNVBuVQ>? NFL4U2szPGh? MX\pcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25iaX7keYNm\CCkeTDEc5g> M1\UT|I1PjN7MEGz
HCT116 NInPTIFCeG:ydH;zbZMhSXO|YYm= NHrIXJc2dU1? M3;4NlI1cA>? NX3QW5BlTE2VTx?= NUfZOnJm\W6qYX7j[ZMh[XCrZ3XubY4ucW6mdXPl[EBk\WyuIHTlZZRp M3HmWVI1PjJ4NUKy
MCF-7  Mkn2RZBweHSxc3nzJGF{e2G7 NF;TXXQxNjGvTR?= MUO2bC=> NYniO3NV\W6qYX7j[ZMhe2m{dHnuc4wucW6mdXPl[EBieG:ydH;zbZM> NY\yPYpsOjJ5NUG5PFk>
PC-3  MYXBdI9xfG:|aYOgRZN{[Xl? NGDwfWIzdU1? M4S3ZlJp MYDpcoNz\WG|ZYOgU3JKNWmwZIXj[YQh[2WubDDk[YF1cA>? MX:yNlc1PTV6MB?=
U251  M2K1c2Fxd3C2b4Ppd{BCe3OjeR?= MlSxOY1O NHHNSYUzPGh? MUfpcoNz\WG|ZYOgV|EucW6mdXPl[EBk\WyuIHTlZZRp M1jKNlIzPTd7N{i4
HeLa  MljnRZBweHSxc3nzJGF{e2G7 M3nEXVVuVQ>? Ml7HNlRp MoPxbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDj[YxtKGSnYYTo NUDVc29{OjJ3NEWxNlg>
A549 M2DPN2Z2dmO2aX;uJGF{e2G7 Mo\6NE4ydU1? NVewUXJNOjSq Mkmyd5VxeHKnc4Pld{BUXTFzMke0MYlv\HWlZXSgZ4VtdCCmZXH0bC=> MWOyNlQ3Pjl4MB?=
pDCs Ml:5SpVv[3Srb36gRZN{[Xl? NULIRWNYOTCvTR?= NFrubHMxNjWq NX3iW4MzyqC{ZXT1Z4V{KHSqZTDpcoR2[3Srb36gc4YhUU[QLd8xJIJ6KHO|Ul7BOFA> M1jNdVIzOzl4NUm5
BGC-823 MWjGeY5kfGmxbjDBd5NigQ>? M{f6TlVuVQ>? M2jDe|Jp MUjpcohq[mm2czD0bIUhemG2ZTDv[kBifXSxcHjh[4lkKGOnbHzz M2ezOVIzOzJ{MUWy
U937 MXfGeY5kfGmxbjDBd5NigQ>? M13IflJuVQ>? Mnm1NVJp NY\1cJlZ\GWlcnXhd4V{KHSqZTDheZRweGijZ4mgdoF1cW0EoB?= NVTaZYZZOjJzNUWxOVA>
Marc-145 NXn6e2tFTnWwY4Tpc44hSXO|YYm= M2XyeFVuVQ>? MnnjNVIwOjRxM{\o NVe1cVB7emWmdXPld{B1cGViUGLSV3YhfGm2ZYLzJIFv\CC2aHWgdJJwfGWrbjDlfJBz\XO|aX;u Mn\ONlIyOTl7MEC=
HBx  NXjDZnVoSXCxcITvd4l{KEG|c3H5 MWSxNI1O MYS0PIg> MYLEUXNQ MlfFbY5kemWjc3XzJINmdGxiZHXheIg> MUmyNlAzODB5OB?=
MCF-7 NVTkfHFxTnWwY4Tpc44hSXO|YYm= NGjW[YIyOG2P NYO1SIV4PDiq NUTDR2s2[myxY3vzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KGKxcoTlfo9ucWJ? NXLINoxwOjF7M{G5N|c>
RMPI8226  MojsSpVv[3Srb36gRZN{[Xl? NXPiXpBYPW2P MnrUNYg> NHnYcpZ{fXCycnXzd4V{KHSqZTDs[ZZmdCCxZjDheZRweGijZ4mgeY5l\XJiboX0dolmdnRiZHXwcIV1cW:w NVHBc3B7OjF7MUW2NlA>
PC12/TetOn MXPGeY5kfGmxbjDBd5NigQ>? NFn6cWExNjFxMX3N MnvFNVhp MlvmcIVi\HNidH:g{tEue3mwKGfULUBi[2O3bYXsZZRqd25uIITvfIlkcXS7LDDhcoQhd2yrZ3;t[ZIh\m:{bXH0bY9vyqB? M4qzVlIyQTB4NkW5
HeLa  NHTiVGdEgXSxdH;4bYNqfHliQYPzZZk> M3LUSVJuVQ>? M1fSWFI1cA>? M4L5dolvcGmkaYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKHOrbHnibY5qdiC2bzDI[WxiKGOnbHzzMi=> NU\JPGVzOjF6N{WzPFU>
Jurkat NXTJWIpMTnWwY4Tpc44hSXO|YYm= NETZWokyOG2P NUD4epR7OWh? MWfk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{NUmLIHHu[EB1cGViZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| NWf3TlE4OjF6NkSwN|c>
K562 NHr6XWlHfW6ldHnvckBCe3OjeR?= NFzNXlAyOG2P NWrKZWxNOWh? NWXWenNI\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEyFMz3JTUBidmRidHjlJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> MY[yNVg3PDB|Nx?=
Nara-H M1;GXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu1OY1O NVzObnd4PDiq M3j3[IVvcGGwY3XzJJRmdXOrcn;sbY12e22nZHnheIVlKHO3cIDy[ZN{cW:wIH;mJG5iemFvSDDj[YxtKHC{b3zp[oVz[XSrb36= NFjQdIozOThyNUCzNy=>
HUVECs MoTaSpVv[3Srb36gRZN{[Xl? MoXFNVBuVQ>? M4DhV|AvPWh? MUXk[YNz\WG|ZYOgeIhmKEGJRT3CV2FqdmS3Y3XkJIF2fG:yaHHnfUBt\X[n NWjw[WdwOjF2Nki1PVI>
HepG2 NEXCOG5CeG:ydH;zbZMhSXO|YYm= NGLMeZIzdU1? NFn2fJUycA>? NXLmWoNQ\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQh[2WubDDk[YF1cA>? M2TqSFIyPDV|Nkmx

... Click to View More Cell Line Experimental Data

In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
+ Expand

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
+ Expand
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
+ Expand
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Formulation: Saline
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)
In vivo water 10mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID